Analog Devices increased by 16% over the last month. You might feel inspired to purchase more stock, or perhaps you are considering reducing your holdings.
As of January 29, 2026, Advanced Micro Devices (AMD) stock has outperformed most of its peers over the last year. Nevertheless, how does it really stack up against competitors that are rapidly growing in the flourishing AI and data-center market?
Robert Half International Q4 Earnings & Revenues Beat Estimates — Positive
RHI Zacks Investment Research — January 30, 2026RHI tops Q4 earnings and revenue estimates despite year-over-year declines, as Talent Solutions weakens while Protiviti shows relative resilience.
3 Top Copper Stocks to Watch as Copper Prices Skyrocket: BHP, FCX, SCCO — Positive
BHP FCX SCCO 24/7 Wall Street — January 30, 2026Major copper producers rallied Thursday as the red metal extended its fourth-quarter run, driven by supply disruptions in South America, China's infrastructure stimulus, and accelerating demand from electric vehicle and renewable energy sectors.
Diageo tipped for upside if it leans further into the mainstream — Positive
DEO Proactive Investors — January 30, 2026Diageo PLC (LSE:DGE) could revive performance if it leans harder into mainstream spirits and steps back from premiumisation, that's according to analysts at RBC, who have repeated an 'Outperform' rating and £20.00 price target. RBC said the most plausible route to recovery is a bigger push into mainstream price points and a less passive stance on category growth.
Protalix wins EU panel backing for expanded dosing of Fabry disease drug — Positive
PLX Proactive Investors — January 30, 2026Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency's human medicines committee has issued a positive opinion recommending approval of an expanded dosing regimen for Elfabrio, its treatment for Fabry disease, in adult patients. The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a 2 mg/kg every-four-weeks dosing schedule for Elfabrio in adult Fabry patients who are stable on enzyme replacement therapy, following a re-examination of the application.
Chevron delivers mixed earnings for fourth quarter — Neutral
CVX Proactive Investors — January 30, 2026Chevron Corporation (NYSE:CVX, XETRA:CHV) posted mixed earnings for the fourth quarter, with profit above Wall Street estimates but revenue falling short. Adjusted earnings for the period were $3 billion, or $1.52 per share, exceeding analyst expectations of roughly $1.45 per share.
Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures — Positive
BSX Zacks Investment Research — January 30, 2026Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Ares Capital (ARCC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates — Positive
ARCC Zacks Investment Research — January 30, 2026Besides Wall Street's top-and-bottom-line estimates for Ares Capital (ARCC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Unveiling Lilly (LLY) Q4 Outlook: Wall Street Estimates for Key Metrics — Neutral
LLY Zacks Investment Research — January 30, 2026Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Unveiling MPLX LP (MPLX) Q4 Outlook: Wall Street Estimates for Key Metrics — Positive
MPLX Zacks Investment Research — January 30, 2026Beyond analysts' top-and-bottom-line estimates for MPLX LP (MPLX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics — Neutral
ABBV Zacks Investment Research — January 30, 2026Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Insights Into Yum (YUM) Q4: Wall Street Projections for Key Metrics — Neutral
YUM Zacks Investment Research — January 30, 2026Evaluate the expected performance of Yum (YUM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Countdown to Uber (UBER) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS — Neutral
UBER Zacks Investment Research — January 30, 2026Get a deeper insight into the potential performance of Uber (UBER) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Curious about CME (CME) Q4 Performance? Explore Wall Street Estimates for Key Metrics — Neutral
CME Zacks Investment Research — January 30, 2026Evaluate the expected performance of CME (CME) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Suncor Energy (SU) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures — Neutral
SU Zacks Investment Research — January 30, 2026Get a deeper insight into the potential performance of Suncor Energy (SU) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Leucipa Rollout Strengthens Baker Hughes' Digital Energy Footprint — Positive
BKR Zacks Investment Research — January 30, 2026BKR lands a multi-year deal with Expand Energy to deploy AI-powered Leucipa across shale wells, aiming to lift efficiency through real-time analytics.
VLY Stock Rallies 3.3% as Q4 Earnings Beat on Higher NII & Fee Income — Positive
VLY Zacks Investment Research — January 30, 2026Valley National shares gain 3.3% after Q4 earnings top estimates, driven by higher net interest income, strong fee income growth and rising loans and deposits.
Sandisk stock soars 14% after blowout earnings report showing overwhelming AI demand — Positive
SNDK CNBC — January 30, 2026Sandisk blew away second-quarter earnings expectations and delivered strong third-quarter revenue guidance. The flash storage memory company reported 64% growth in its data center business.
The Magnificent 7 Are Starting To Look Too Cheap To Ignore — Positive
AAPL MSFT 24/7 Wall Street — January 30, 2026The Magnificent Seven sailed into 2026 in a rather muted spot. While there has been a notable divergence in performance among the members, I do think that the group remains worth sticking with for the long haul, especially the names that have been viciously marked down.